Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist used to improve glycemic control in Type 2 diabetes and for chronic weight management. It is a 39-amino acid synthetic peptide that is often supplied in 20 mg strengths (typically 20 mg/0.5 mL or similar concentrations in compounding scenarios) for once-weekly subcutaneous injection.











Reviews
There are no reviews yet.